Small molecule inhibition of the ubiquitin-specific protease USP2 accelerates cyclin D1 degradation and leads to cell cycle arrest in colorectal cancer and mantle cell lymphoma models

Journal of Biological Chemistry

Volumn 291, Issue 47, 2016, Pages 24628-24640

  Davis, Mindy I ^a   Pragani, Rajan ^a   Fox, Jennifer T ^a   Shen, Min ^a   Parmar, Kalindi ^b   Gaudiano, Emily F ^b   Liu, Li ^a   Tanega, Cordelle ^a   McGee, Lauren ^a   Hall, Matthew D ^a   McKnight, Crystal ^a   Shinn, Paul ^a   Nelson, Henrike ^a   Chattopadhyay, Debasish ^c   D'Andrea, Alan D ^b   Auld, Douglas S ^a,d   DeLucas, Larry J ^c   Li, Zhuyin ^a   Boxer, Matthew B ^a   Simeonov, Anton ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSAYS; CELL CULTURE; CYTOLOGY; DISEASES; DNA; MOLECULES; REPAIR;

ANTI-PROLIFERATIVE; CELL-CYCLE ARREST; DNA DAMAGE RESPONSE; FLOW CYTOMETRY ASSAYS; HOMOLOGOUS RECOMBINATION; PROTEIN DEGRADATION; REGULATORY NETWORK; SMALL MOLECULE INHIBITOR;

CELLS;

ANTINEOPLASTIC AGENT; CYCLIN D1; DEUBIQUITINASE; ML 364; PROTEIN USP2; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN; PROTEINASE; PROTEINASE INHIBITOR; TUMOR PROTEIN; USP2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOCHEMISTRY; CANCER CELL LINE; CELL CYCLE ARREST; COLORECTAL CANCER; DNA DAMAGE RESPONSE; DNA REPAIR; DRUG STRUCTURE; ENZYME INHIBITION; FLOW CYTOMETRY; HOMOLOGOUS RECOMBINATION; HUMAN; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CHEMISTRY; COLORECTAL TUMOR; DNA DAMAGE; DRUG EFFECTS; GENETICS; LYMPHOMA, MANTLE-CELL; METABOLISM; TUMOR CELL LINE;

CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN D1; DNA DAMAGE; DNA REPAIR; ENDOPEPTIDASES; HUMANS; LYMPHOMA, MANTLE-CELL; NEOPLASM PROTEINS; PROTEASE INHIBITORS; PROTEOLYSIS;

EID: 84995948126     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.738567     Document Type: Article

References (37)

1. Komander, D., and Rape, M. (2012) The ubiquitin code. Annu. Rev. Biochem. 81, 203-229
2. Stevenson, L. F., Sparks, A., Allende-Vega, N., Xirodimas, D. P., Lane, D. P., and Saville, M. K. (2007) The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 26, 976-986
3. Graner, E., Tang, D., Rossi, S., Baron, A., Migita, T., Weinstein, L. J., Lechpammer, M., Huesken, D., Zimmermann, J., Signoretti, S., and Loda, M. (2004) The isopeptidase USP2a regulates the stability of fatty-acid synthase in prostate cancer. Cancer Cell 5, 253-261
4. Shan, J., Zhao, W., and Gu, W. (2009) Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol. Cell 36, 469-476
5. Tong, X., Buelow, K., Guha, A., Rausch, R., and Yin, L. (2012) USP2a protein deubiquitinates and stabilizes the circadian protein CRY1 in response to inflammatory signals. J. Biol. Chem. 287, 25280-25291
6. Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda, D. K., and Varshavsky, A. (1989) A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243, 1576-1583
7. Chen, Z. J., and Sun, L. J. (2009) Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33, 275-286
8. Cohen, P., and Tcherpakov, M. (2010) Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 143, 686-693
9. Priolo, C., Tang, D., Brahamandan, M., Benassi, B., Sicinska, E., Ogino, S., Farsetti, A., Porrello, A., Finn, S., Zimmermann, J., Febbo, P., and Loda, M. (2006) The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res. 66, 8625-8632
10. Gansler, T. S., Hardman, W., 3rd, Hunt, D. A., Schaffel, S., and Hennigar, R. A. (1997) Increased expression of fatty-acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum. Pathol. 28, 686-692
11. Hunt, D. A., Lane, H. M., Zygmont, M. E., Dervan, P. A., and Hennigar, R. A. (2007) MRNA stability and overexpression of fatty-acid synthase in human breast cancer cell lines. Anticancer Res. 27, 27-34
12. Baron, A., Migita, T., Tang, D., and Loda, M. (2004) Fatty acid synthase: a metabolic oncogene in prostate cancer? J. Cell. Biochem. 91, 47-53
13. Alao, J. P. (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 6, 24
14. Li, J. Y., Gaillard, F., Moreau, A., Harousseau, J. L., Laboisse, C., Milpied, N., Bataille, R., and Avet-Loiseau, H. (1999) Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am. J. Pathol. 154, 1449-1452
15. Fernàndez, V., Hartmann, E., Ott, G., Campo, E., and Rosenwald, A. (2005) Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J. Clin. Oncol. 23, 6364-6369
16. Bozza, W. P., Liang, Q., Gong, P., and Zhuang, Z. (2012) Transient kinetic analysis of USP2-catalyzed deubiquitination reveals a conformational rearrangement in the K-48-linked diubiquitin substrate. Biochemistry 51, 10075-10086
17. Renatus, M., Parrado, S. G., D'Arcy, A., Eidhoff, U., Gerhartz, B., Hassiepen, U., Pierrat, B., Riedl, R., Vinzenz, D., Worpenberg, S., and Kroemer, M. (2006) Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure 14, 1293-1302
18. Flohr, S., Furet, P., Imbach, P., Hommel, U., Litscher, H.-U., Gil Parrado, S., Hassiepen, U., and Zimmermann, J. (January 25, 2007) U. S. Patent WO2007009715
19. Issaenko, O. A., and Amerik, A. Y. (2012) Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell Cycle 11, 1804-1817
20. Nicholson, B., Leach, C. A., Goldenberg, S. J., Francis, D. M., Kodrasov, M. P., Tian, X., Shanks, J., Sterner, D. E., Bernal, A., Mattern, M. R., Wilkinson, K. D., and Butt, T. R. (2008) Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities. Protein Sci. 17, 1035-1043
21. Seidel, S. A., Wienken, C. J., Geissler, S., Jerabek-Willemsen, M., Duhr, S., Reiter, A., Trauner, D., Braun, D., and Baaske, P. (2012) Label-free microscale thermophoresis discriminates sites and affinity of protein-ligand binding. Angew Chem. Int. Ed. Engl. 51, 10656-10659
22. Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K. K., Bradner, J. E., and Kaelin, W. G., Jr. (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305-309
23. Yen, H. C., Xu, Q., Chou, D. M., Zhao, Z., and Elledge, S. J. (2008) Global protein stability profiling in mammalian cells. Science 322, 918-923
24. Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F., Zagozdzon, A., Goswami, T., Wang, Y. E., Clark, A. B., Kunkel, T. A., van Harn, T., Xia, B., Correll, M., Quackenbush, J., et al. (2011) A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 474, 230-234
25. Halford, B. (2012) From Discovery To Drug. Chemical & Engineering News Archive 90, 34-35
26. Adams, J., and Kauffman, M. (2004) Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Investigation 22, 304-311
27. +channel. J. Biol. Chem. 288, 5389-5397
28. Byun, S., Lee, S. Y., Lee, J., Jeong, C. H., Farrand, L., Lim, S., Reddy, K., Kim, J. Y., Lee, M. H., Lee, H. J., Bode, A. M., Won Lee, K., and Dong, Z. (2013) USP8 is a novel target for overcoming gefitinib resistance in lung cancer. Clin. Cancer Res. 19, 3894-3904
29. Marampon, F., Gravina, G., Ju, X., Vetuschi, A., Sferra, R., Casimiro, M., Pompili, S., Festuccia, C., Colapietro, A., Gaudio, E., Di Cesare, E., Tombolini, V., and Pestell, R. G. (2016) cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage. Oncotarget 7, 5383-5400
30. Yasgar, A., Shinn, P., Jadhav, A., Auld, D., Michael, S., Zheng, W., Austin, C. P., Inglese, J., and Simeonov, A. (2008) Compound management for quantitative high-throughput screening. JALA 13, 79-89
31. Inglese, J., Auld, D. S., Jadhav, A., Johnson, R. L., Simeonov, A., Yasgar, A., Zheng, W., and Austin, C. P. (2006) Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. U.S.A. 103, 11473-11478
32. Copeland, R. A. (2005) Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, pp. 48-80, John Wiley & Son, Inc., Hoboken, NJ
33. Lai, R., McDonnell, T. J., O'Connor, S. L., Medeiros, L. J., Oudat, R., Keating, M., Morgan, M. B., Curiel, T. J., and Ford, R. J. (2002) Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk. Res. 26, 849-855
34. Mistry, H., Hsieh, G., Buhrlage, S. J., Huang, M., Park, E., Cuny, G. D., Galinsky, I., Stone, R. M., Gray, N. S., D'Andrea, A. D., and Parmar, K. (2013) Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol. Cancer Ther. 12, 2651-2662
35. Pierce, A. J., Johnson, R. D., Thompson, L. H., and Jasin, M. (1999) XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13, 2633-2638
36. Avdeef, A. (2007) Pharmacokinetic Optimization in Drug Research (Testa, B., van de Waterbeemd, H., Folkers, G., and Guy, R., Eds.) pp. 305-325, Verlag Helvetica Chimica Acta, Zürich, Switzerland
37. Di, L., Kerns, E. H., Li, S. Q., and Petusky, S. L. (2006) High throughput microsomal stability assay for insoluble compounds. Int. J. Pharm. 317, 54-60